Showing 2636 results
- https://www.novartis.com/news/media-releases/novartis-delivered-solid-performance-second-quarter-strong-innovation-and-progress-new-launchesSales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3…
- https://www.novartis.com/news/media-releases/novartis-solide-performance-au-deuxieme-trimestre-grace-la-force-de-linnovation-et-aux-progres-des-nouveaux-lancementsCroissance des ventes, du résultat opérationnel core[1] et du BPA core (tcc[1]) des activités poursuivies[2] au T2: Le chiffre d'affaires net s'est élevé à USD 12,7 milliards (-5%, +6% tcc). Le…
- https://www.novartis.com/news/media-releases/sandoz-announces-us-launch-glatopatm-first-generic-competitor-copaxone-20mgGlatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Sandoz has begun shipping to US customers…
- https://www.novartis.com/news/media-releases/novartis-highlights-strong-innovation-momentum-its-second-meet-novartis-management-investor-dayStrong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and…
- https://www.novartis.com/news/media-releases/alcon-receives-european-approval-new-trifocal-presbyopia-correcting-intraocular-lens-patients-undergoing-cataract-surgeryInnovative AcrySof® IQ PanOptix® trifocal intraocular lens design to improve near to intermediate vision and increase independence from glasses More than three million cataract surgeries…
- https://www.novartis.com/news/media-releases/novartis-presents-new-data-from-large-european-study-reinforcing-benefit-first-line-tasigna-newly-diagnosed-patients-cmlPatients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of…
- https://www.novartis.com/news/media-releases/novartis-issues-egm-invitation-and-shareholder-information-brochure-sandoz-publishes-listing-prospectus-ahead-proposed-spin-voteAd hoc announcement pursuant to Art. 53 LR Invitation to Novartis Extraordinary General Meeting on September 15, 2023, and Shareholder Information Brochure issuedSandoz Listing Prospectus…
- https://www.novartis.com/news/media-releases/novartis-publiziert-einladung-und-aktionarsbroschure-zur-ausserordentlichen-generalversammlung-sandoz-veroffentlicht-den-kotierungsprospekt-im-vorfeld-der-abstimmung-zum-vorgeschlagenen-spinAd-hoc-Meldung nach Art. 53 LR Einladung zur ausserordentlichen Generalversammlung von Novartis am 15. September 2023 und Informationsbroschüre für Aktionärinnen und Aktionäre publiziertSandoz…
- https://www.novartis.com/news/media-releases/novartis-publie-linvitation-lage-et-la-brochure-dinformation-aux-actionnaires-sandoz-publie-le-prospectus-de-cotation-avant-le-vote-sur-la-proposition-de-scissionAnnonce ad hoc en vertu de l’art. 53 LR Invitation à l’assemblée générale extraordinaire de Novartis du 15 septembre 2023 et publication d’une brochure d’information destinée…
- https://www.novartis.com/news/media-releases/novartis-announces-data-show-majority-patients-polycythemia-vera-treated-jakavi-achieved-long-term-disease-controlPreplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year[1] In the study, 83% of patients in…
Pagination
- ‹ Previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- 264
- › Next page